ALB and type 2 diabetes mellitus: Previous studies have shown that administering 2 weeks of CSII to newly diagnosed patients with type 2 diabetes resulted in almost a 1% decrease in HbA1c and an 8% decrease in glycated albumin, while the time taken to achieve glycemic targets was around 3 to 5 days [13, 21].